+

WO2011059198A3 - Composition pharmaceutique contenant un bisphosphonate - Google Patents

Composition pharmaceutique contenant un bisphosphonate Download PDF

Info

Publication number
WO2011059198A3
WO2011059198A3 PCT/KR2010/007643 KR2010007643W WO2011059198A3 WO 2011059198 A3 WO2011059198 A3 WO 2011059198A3 KR 2010007643 W KR2010007643 W KR 2010007643W WO 2011059198 A3 WO2011059198 A3 WO 2011059198A3
Authority
WO
WIPO (PCT)
Prior art keywords
bisphosphonate
stomach
take
pharmaceutical composition
irritation due
Prior art date
Application number
PCT/KR2010/007643
Other languages
English (en)
Korean (ko)
Other versions
WO2011059198A2 (fr
Inventor
유무희
차봉진
김정훈
장선우
이정우
유동성
Original Assignee
동아제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동아제약주식회사 filed Critical 동아제약주식회사
Publication of WO2011059198A2 publication Critical patent/WO2011059198A2/fr
Publication of WO2011059198A3 publication Critical patent/WO2011059198A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant un bisphosphonate qui présente un effet de traitement de l'ostéoporose, une substance macromoléculaire sensible au pH, un agent moussant et un agent tampon. La composition selon la présente invention n'exige pas d'ingérer une grande quantité d'eau lors de l'administration, et son pouvoir tampon est suffisant pour maintenir le pH de l'estomac à une valeur supérieure ou égale à 3,5 après la prise, empêchant ainsi toute irritation œsophagienne due à un reflux gastrique et ne nécessitant pas de rester debout dans une position particulière. De même, même si le pH de l'intérieur de l'estomac chute en dessous de 3,5 chez les patients dont l'acidité gastrique est excessivement faible, l'irritation œsophagienne du reflux gastrique peut être empêchée par formation d'un polymère RAFT de type flottant et gonflant ; la facilité de prise des médicaments de type bisphosphonate par le patient dans un traitement de longue durée est donc singulièrement améliorée ; la composition présente un effet moussant qui se déroule en deux étapes.
PCT/KR2010/007643 2009-11-10 2010-11-02 Composition pharmaceutique contenant un bisphosphonate WO2011059198A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0108284 2009-11-10
KR1020090108284A KR101118794B1 (ko) 2009-11-10 2009-11-10 비스포스포네이트를 함유하는 약학 조성물

Publications (2)

Publication Number Publication Date
WO2011059198A2 WO2011059198A2 (fr) 2011-05-19
WO2011059198A3 true WO2011059198A3 (fr) 2011-10-20

Family

ID=43992186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/007643 WO2011059198A2 (fr) 2009-11-10 2010-11-02 Composition pharmaceutique contenant un bisphosphonate

Country Status (2)

Country Link
KR (1) KR101118794B1 (fr)
WO (1) WO2011059198A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020080018A (ko) * 2001-04-10 2002-10-23 한국화학연구원 비스포스포네이트 골 흡수억제제의 이식형 서방성제제
US20040208925A1 (en) * 2003-04-18 2004-10-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dispersible alendronate microparticle formulation
WO2008148478A2 (fr) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Système de rétention gastrique renfermant un corps d'alginate
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
JP2009167200A (ja) * 1996-05-17 2009-07-30 Merck & Co Inc 発泡性ビスホスホネート製剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009167200A (ja) * 1996-05-17 2009-07-30 Merck & Co Inc 発泡性ビスホスホネート製剤
KR20020080018A (ko) * 2001-04-10 2002-10-23 한국화학연구원 비스포스포네이트 골 흡수억제제의 이식형 서방성제제
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
US20040208925A1 (en) * 2003-04-18 2004-10-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dispersible alendronate microparticle formulation
WO2008148478A2 (fr) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Système de rétention gastrique renfermant un corps d'alginate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATIL, J. M. ET AL.: "Trends in floating drug delivery systems.", JOURNAL OF SCIENTIFIC & INDUSTRIAL RESEARCH, vol. 65, January 2006 (2006-01-01), pages 11 - 21, XP002681566 *

Also Published As

Publication number Publication date
KR101118794B1 (ko) 2012-06-13
WO2011059198A2 (fr) 2011-05-19
KR20110051622A (ko) 2011-05-18

Similar Documents

Publication Publication Date Title
IL250641B (en) Pharmaceutical preparations for inhibiting nhe-mediated antiport in the treatment of disorders related to fluid retention or salt overload and disorders in the digestive system
EA018193B3 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
WO2009007411A3 (fr) Inhibition de la formation des ages
WO2007119177A3 (fr) Formulations à libération modifiée et méthodes de traitement de maladie intestinale inflammatoire
BRPI0518093A (pt) dose de nanopartìculas a um paciente, método de intensificação do transporte paracelular intestinal ou o transporte paracelular de sangue do cérebro e dose oral de nanopartìculas que intensifica o transporte paracelular intestinal ou o transporte paracelular de sangue do cérebro
EP2101757A4 (fr) Composé pour le traitement ou la prévention de maladies en relation avec la prostate et compositions pharmaceutiques de système d'administration par le colon contenant ce composé
HK1202815A1 (en) Liquid compositions of calcium acetate
UA103906C2 (ru) Жидкая фармацевтическая композиция, которая содержит парацетамол
EP1992361A4 (fr) Remede ou agent preventif contre l'ulcere digestif
WO2011066980A3 (fr) Formes de dose orale avec risque réduit d'abus de médicaments
CO6341514A2 (es) Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástrica
WO2009019835A1 (fr) Médicament liquide contenant un mélange d'extrait pharmacologique brut
EP2050442A4 (fr) Composition pharmaceutique destinée à la prévention et/ou au traitement d'une maladie osseuse, aliment fonctionnel ou aliment diététique contenant la composition, et préparation pharmaceutique contenant la composition en tant que principe actif
EP2231148A4 (fr) Composition pharmaceutique utilisée dans le traitement et la prévention d'une maladie cardiaque
WO2011059198A3 (fr) Composition pharmaceutique contenant un bisphosphonate
EP2801358A3 (fr) Utilisation de la nicotine pour diminuer la douleur dans la région rénale chez l'homme
WO2007143311A3 (fr) Aide à la consommation d'une forme posologique de médicament solide
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2008068584A3 (fr) Système de libération de médicament gastro-intestinal multiparticulaire à configuration hétérogène
WO2009051217A1 (fr) Préparation à absorption percutanée renfermant du fentanyl
AU2012311964B2 (en) Buffered upper GI absorption promoter
WO2010066437A3 (fr) Composition aqueuse contenant du dexpanthénol et du chlorure de sodium
EP2351567A4 (fr) Composition pharmaceutique et medicament pour la prevention et le traitement de diabetes ou de l'obesite comprenant comme principe actif, un compose qui inhibe l'activation de dipeptidyl peptidase-iv
IL240323A0 (en) Preparations based on 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazio-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl Piperadine-4-carboxylic acid or salts, to increase levels of platelets in human blood
BRPI0408805A (pt) composição farmacêutica contendo complexo de platina e método de fabricação da mesma

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10830131

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载